GenEdit and Editas announce a worldwide, exclusive license and collaboration to enable safer and more effective delivery of CRISPR-based therapeutics.
GenEdit, Inc. is biotechnology company focused on the development of novel, non-viral, nanoparticle-based delivery technologies...
